Endpoints News
Apogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, Ebglyss
Apogee Therapeutics said its moderate-to-severe eczema candidate could offer much more convenient dosing over standard treatments based on its latest mid-stage results.
Monday’s Phase 2 maintenance data highlighted the efficacy of …